Infectious Disease

Cost-conscious guidelines, government regulation, market-level incentives can ensure access, help patients save money.

The action allows for medicinal products to be authorized on a conditional basis for seriously debilitating or life-threatening diseases or for use in emergency situations in response to public health threats in the European Union.

Baloxavir marboxil and oseltamivir are options for treating uncomplicated influenza.

Originally approved in 2018, baloxavir marboxil is indicated for patients aged 12 years and older.

The new molecules are repurposed form a drug that’s been used for over 80 years.

The objective of the study was to investigate associations between symptoms of gastroenteritis and the presence of airborne norovirus, as well as investigating the size of norovirus-carrying particles.

Study results suggest that infusing foods with green tea extract may lower consumers' chances of catching norovirus when eating contaminated food.

Pharmacists can play an important role in educating patients about hand hygiene measures during COVID-19.

Cefiderocol approved for the treatment with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

What is causing a young, normally healthy person to suddenly fall ill and need immediate medical attention?

The combination of imipenem-cilastatin and relebactam was previously approved by the FDA to treat patients with complicated urinary tract infections and complicated intra-abdominal infections who have limited or no alternative treatment options.

Remdesivir is not approved by the FDA. However, EUA allows for distribution and emergency use for treatment of COVID-19.

New research on the structure of HIV has revealed a promising novel drug target for treating HIV infection.

Remdesivir is not approved by the FDA nor licensed or approved anywhere in the world.

Case studies focusing on infectious disease.

The length of time patients remained contagious after the end of their symptoms, however, ranged from 1 to 8 days.

Several pharmaceutical companies are racing to develop an effective treatment for the virus that is now a global pandemic.

The new guidance for industry (GFI) document, “Policy for Temporary Compounding of Certain Alcohol-Based Hand Sanitizer Products,” was released Saturday.

Thermo Fisher Scientific’s test is designed to provide patient results within 4 hours of a sample being received by a lab.

In the United States, the CDC has confirmed 938 cases and 29 deaths, as well as 771 patients under investigation.

The United States now has more than 100 confirmed cases and 10 deaths, according to the CDC.

The greatest risk is still to people who have been in close contact with COVID-19 patients, according to the CDC.

The virus has now reached all continents except Antarctica, with cases reported in 47 countries.

The FDA has approved Xenleta (Lefamulin, from Nabriva Therapeutics) for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms.

As pharmacists, patients are inquiring about these kits already, and recommending such items can help prevent a lot of worry.

The FDA and the White House also announced new initiatives to combat the novel coronavirus.

Dengue is endemic in the United States territories of American Samoa, Guam, Puerto Rico, and the US Virgin Islands.

Fears surrounding the COVID-19 outbreak have had major effects even in unaffected areas, including face mask shortages, a falling stock market, and many unsubstantiated rumors.

Although the number of US cases is still low, experts are raising concerns that the US reliance on China for pharmaceutical ingredients could result in drug shortages as Chinese officials battle the outbreak.

As the most accessible health care providers, pharmacists can play a key role in counseling patients on the best practices for infection control and prevention.